mRNA-Based Therapies Beyond Vaccines

What makes mRNA different from gene therapy

A 2024 Lancet review describes mRNA effects as rapid, potent and transient, with no need to enter the nucleus. [1] That is different from approaches that add or edit genes; compare RNA Therapy vs Gene Therapy and Gene Addition and Gene Therapy Explained. The same review lists remaining challenges: mRNA stability, duration of expression, delivery efficiency and targeting. [1]

Delivery usually relies on carriers such as lipid nanoparticles; see Lipid Nanoparticles and Non-Viral Delivery.

Where the evidence stands

Approved status. I read the FDA list of licensed cellular and gene therapy products on 2026-10-22 and did not find an individualized mRNA cancer therapy on it. [2] That is a statement about one list, not a global regulatory survey. A product being in clinical trials does not mean it is approved.

The best-described human example: individualized neoantigen therapy. In KEYNOTE-942, a randomized, open-label phase 2b trial, 157 people with completely resected high-risk melanoma received either mRNA-4157 (V940, later named intismeran autogene) plus the immunotherapy drug pembrolizumab or pembrolizumab alone, in a 2:1 split. The mRNA therapy is described as an individualized neoantigen therapy, meaning tailored to each person. [3]

• Original report (about 2 years' follow-up). Recurrence or death occurred in 22% (24 of 107) with the combination versus 40% (20 of 50) with pembrolizumab alone. The hazard ratio was 0.561 (95% CI 0.309 to 1.017; p = 0.053), which was not below the usual 0.05 threshold and has a confidence interval that includes no effect. [3]


• Safety. Grade 3 or higher treatment-related adverse events occurred in 25% on the combination and 18% on pembrolizumab alone, and most events were grade 1 or 2. [3]


• Five-year update. The hazard ratio for recurrence-free survival was 0.510 (95% CI 0.294 to 0.887). The update's five-year analyses were descriptive, and overall survival showed a favorable trend with a wide interval (hazard ratio 0.471; 95% CI 0.165 to 1.345). [4]


• Funding and limits. The trial was funded by Moderna with Merck. [3] It was small, open label, used one cancer type, and its control arm had 50 people. These are investigational results from one trial program; later publications from one trial are not independent confirmations. See Cancer-Related Gene and Cell Therapies: Context.

Other uses (protein replacement, genome-editing delivery, infectious disease). The Lancet review summarizes these as an expanding field of preclinical and clinical studies. [1] Insufficient evidence was found in the sources read to describe results for any single non-vaccine product other than the melanoma example; see Investigational Gene and RNA Applications.

Who should be careful

• People with cancer should discuss trials with their oncologist rather than buy anything. See Finding and Understanding Registered Clinical Trials.
• "mRNA" is not a synonym for effective or safe. Each product needs its own evidence.
• Claims about "mRNA supplements" or clinic-made mRNA products have no support in the sources read and are marketing claims. See Medical Tourism for Unproven Treatments.